United Kingdom-based AstraZeneca has completed sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma, it was reported yesterday.
The deal is valued at USD350m. Under the terms of the deal, Covis will also make conditional sales-related payments for the three drugs of up to USD21m to AstraZeneca over four years starting from 2019.
The divested rights by AstraZeneca to Covis Pharma includes markets outside the US and the US royalties for the three over-the-counter drugs. Omnaris is an inhaled anti-inflammatory maintenance therapy that is administered through a metered-dose inhaler to help control persistent asthma. The other two products were developed for the treatment of nasal symptoms resulting from seasonal allergic and allergic/non-allergic perennial rhinitis.
The deal was first announced in November this year and does not include the transfer of any AstraZeneca employees or facilities to Covis.
Novartis to acquire Xiidra drug from Takeda
Amerigen wins US FDA approval for generic Penicillamine in 250 mg capsules
Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings
Shattuck Labs Initiates Phase 1 Clinical Trial of SL-279252
Amerigen Pharmaceuticals Limited wins US FDA approval for Penicillamine Capsules USP in 250 mg
Novus Therapeutics Launches USD 10.7m Registered Direct Offering Priced At-the-Market